问题 › 我们的营销支出没有效果 › 保险经纪商
对保险经纪商佣金没有提升作用的营销，大多投在无法触及带来71%收入的续保账户的渠道上，判断依据是无法追溯到承保人支付的数据。 保险经纪商面临的问题不是通用版本。71%的收入来自承保人佣金，而把增量8%转向费用，需要替换142个续保账户，并使短期利润率下降1.8到2.3个百分点——因此忽略19.0的答案会明显错误。分析必须从91.2和664开始，而不是从收入开始。
对保险经纪商佣金没有提升作用的营销，大多投在无法触及带来71%收入的续保账户的渠道上，判断依据是无法追溯到承保人支付的数据。 保险经纪商面临的问题不是通用版本。71%的收入来自承保人佣金，而把增量8%转向费用，需要替换142个续保账户，并使短期利润率下降1.8到2.3个百分点——因此忽略19.0的答案会明显错误。分析必须从91.2和664开始，而不是从收入开始。
当渠道错过产生标准佣金的账户，或追踪系统无法将线索与数月后收到的或有佣金关联时，会出现相同结果。
在CFO能把47.8百万的每一元钱分配到产生它的渠道之前，决策取决于谁拿出最大的664或31。
按19.0获取且在当前续保周期内回本的渠道可以继续投入；按91.2获取且要三个周期才回本的渠道则不行，无论664的数字如何。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 续保留存率无法按产生原始佣金的来源拆分。
✓ 支出靠或有佣金预测而非已成交的续保账户来辩护。
✓ 表现最好的渠道，会随报告用19.0还是91.2作为截止值而改变。
通常会让情况更糟的做法。 在修复142个账户的计数方式之前先优化创意和定向，导致基于不可靠数字做出一年自信的决策。
It is for you if you run or finance an insurance broker and cost per acquisition cannot be stated by channel. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家保险经纪商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Kesterline Risk Partners, a sample company profile used for testing rather than a customer — 47.8 million dollars in total revenue from commissions and fees.
Excerpt from a real Percision run · Quick Market Scan · sample company profile
The move. Convert 460 commission accounts to fee retainers, funding a $3-5M digital workbench from productivity gains while staying inside the $4.8m investment ceiling.
| Investment required | $3.0-5.0M total (base $3.0M, upside $5.0M for accelerated digital workbench) |
| Expected return | 3.2-4.8× over 36 months on $3-5M investment, based on +$4.2-8.5M incremental fee revenue at 35-45% gross margin versus current 19% operating margin. |
| Revenue, year 1 | $50.1-51.8M total revenue (+$2.3-4.0M incremental fee) |
| Revenue, year 2 | $54.4-57.9M total revenue (+$6.6-10.1M incremental fee) |
| Revenue, year 3 | $58.2-64.8M total revenue (+$10.4-17.0M incremental fee) |
| Exit criteria | Strategy should be reversed if, within 12 months, pilot conversion rate falls below 15% OR incremental churn exceeds 5% OR producer productivity drops below $600k average; OR if, within 24 months, cumulative fee revenue does not reach $6.6M incremental run-rate. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Go-to-Market & Commercial Strategy, one of 29 engagements the platform runs. For 保险经纪商 it works through 19.0, 91.2, 664 and 31, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
唯一有意义的检验是与生命周期价值和回本期对比，而这两者都因业务而异。在一种模式下优秀的成本，在收入相同的另一种模式下可能是灾难。
覆盖销售周期加一个回本期就够了，不要更长。过早判断会杀死慢生效的渠道；过晚判断会继续资助永不回本的渠道。
先砍掉无法衡量的渠道——风险集中在那里。均匀削减会把正在起作用的渠道和没起作用的一起去掉。
Materially, yes. 71 percent of revenue flows through carrier commissions while shifting an incremental 8 percent to fees would require replacing 142 renewal accounts and cut near-term margin by 1.8 to 2.3 points — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are 19.0, 91.2, 664, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on 19.0 and 91.2. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית